tech
January 13, 2026
Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz
AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz.
TL;DR
- Converge Bio raised $25 million in a Series A funding round led by Bessemer Venture Partners.
- The startup uses generative AI trained on molecular data (DNA, RNA, protein sequences) to accelerate drug discovery.
- Converge Bio offers three integrated AI systems: one for antibody design, one for protein yield optimization, and one for biomarker and target discovery.
- The company has signed 40 partnerships with pharmaceutical and biotech companies and is running about 40 programs on its platform.
- Converge Bio has expanded its team to 34 employees and operates across the U.S., Canada, Europe, and Israel, with expansion into Asia underway.
- The company integrates generative models with predictive models and physics-based simulations to filter and validate molecules, reducing risk.
- This funding round comes about 1.5 years after the company's $5.5 million seed round in 2024.
Continue reading
the original article